ENDEAVOR TO STOP NAUSEA/VOMITING ASSOCIATED WITH PREGNANCY (E-SNAP)

努力停止与怀孕相关的恶心/呕吐 (E-SNAP)

基本信息

  • 批准号:
    10643818
  • 负责人:
  • 金额:
    $ 20万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-13 至 2024-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT ENDEAVOR TO STOP NAUSEA/VOMITING ASSOCIATED WITH PREGNANCY (E-SNAP) Up to 85% of pregnant women experience nausea and vomiting of pregnancy (NVP), which impairs daily function and reduces quality of life. A severe form, hyperemesis gravidarum (HG), affects 0.3-3% of pregnant women and is the most common reason for hospitalization in the first half of pregnancy. Although NVP and HEG usually resolve by mid-pregnancy, symptoms persist into the third trimester in 15--20% of women. HG is associated with preterm birth and small-for gestational age infants as well as termination of desired pregnancies in 14.4% of affected women. Recent studies show that women with severe NVP (sNVP), defined by weight loss or continuation of symptoms beyond 20 weeks gestation, have offspring at risk for structural brain changes and cognitive developmental problems. Despite the frequency and complications of sNVP, only low-quality evidence is available to direct treatment. The NICHD report from the Task Force on Research Specific to Pregnant Women and Lactating Women stated that the drug pipeline for conditions specific to pregnancy is “minimal at best” and listed hyperemesis as an area of need for treatment research. This exploratory/developmental Clinical Trial Planning Grant is a Phase 2 study that will provide data on the acceptability, dose regimen, tolerability and safety of mirtazapine (Remeron®) for the treatment of sNVP that has not responded to at least two standard medications. We will to determine whether a larger randomized controlled trial to evaluate mirtazapine’s efficacy for sNVP is warranted. An FDA application for an IND will be submitted and a DSMB will be constituted. Mirtazapine is prescribed for nausea and vomiting during cancer chemotherapy. Rapid reduction of NVP during mirtazapine treatment has been reported in case series of pregnant women who have not responded to other medications. Mirtazapine impacts the serotonin receptor (similar to ondansetron) as well as three additional receptors involved in the physiologic cascade that results in nausea and emesis. It is a compelling candidate to consider for repurposing to expand therapeutic options for sNVP. Reproductive outcome data for mirtazapine do not indicate an increased risk for birth defects, although the number of women studied is relatively small (≈500). Additionally, pharmacogenetic factors that affect mirtazapine plasma concentrations and thereby affect its tolerability and safety will be considered in the proposed project.
项目总结/摘要 奋进终止妊娠相关恶心/呕吐(E-SNAP) 高达85%的孕妇经历恶心和呕吐的怀孕(NVP),这损害了每天 功能,降低生活质量。妊娠剧吐(HG)是一种严重的形式,影响0.3-3%的孕妇。 这是怀孕前半期住院的最常见原因。虽然NVP和 HEG通常在妊娠中期消退,15- 20%的女性症状持续到妊娠晚期。汞 与早产和小于胎龄儿以及终止所需的 14.4%的受影响妇女怀孕。最近的研究表明,患有严重NVP(sNVP)的女性, 体重减轻或症状持续超过妊娠20周,使后代有结构性 大脑变化和认知发展问题。 尽管sNVP的频率和并发症很高,但只有低质量的证据可供指导 治疗NICHD关于孕妇和哺乳期妇女研究特别工作组的报告 妇女们表示,针对怀孕特定条件的药物管道“充其量是最少的”,并列出了 作为一个需要治疗研究的领域。 这项探索性/开发性临床试验计划资助是一项2期研究,将提供以下数据: 米氮平(Remeron®)治疗sNVP的可接受性、剂量方案、耐受性和安全性 对至少两种标准药物都没有反应我们将确定是否有更大的随机 需要进行对照试验来评估米氮平对sNVP的疗效。FDA的IND申请将 提交并组建DSMB。 米氮平用于治疗癌症化疗期间的恶心和呕吐。NVP快速降低 在对米氮平治疗无反应的孕妇的病例系列中, 其他药物。米氮平影响血清素受体(类似于昂丹司琼)以及三种 参与导致恶心和呕吐的生理级联反应的其他受体。而且是一个引人注目的 考虑重新利用以扩大sNVP的治疗选择的候选人。生殖结局数据 米氮平并不表明出生缺陷的风险增加,尽管研究的妇女人数是 相对较小(约500)。此外,影响米氮平血药浓度的药物遗传学因素 从而影响其耐受性和安全性。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pregnant, miserable, and starving in 21st century America.
  • DOI:
    10.1016/j.xagr.2022.100141
  • 发表时间:
    2023-02
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fejzo MS;MacGibbon KW;Wisner KL
  • 通讯作者:
    Wisner KL
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHERINE L WISNER其他文献

KATHERINE L WISNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHERINE L WISNER', 18)}}的其他基金

ENDEAVOR TO STOP NAUSEA/VOMITING ASSOCIATED WITH PREGNANCY (E-SNAP)
努力停止与怀孕相关的恶心/呕吐 (E-SNAP)
  • 批准号:
    10390898
  • 财政年份:
    2022
  • 资助金额:
    $ 20万
  • 项目类别:
Optimizing Treatment of Mental Illness during Pregnancy:Improving Infant Outcomes
优化妊娠期精神疾病的治疗:改善婴儿的结局
  • 批准号:
    8528927
  • 财政年份:
    2013
  • 资助金额:
    $ 20万
  • 项目类别:
Marce Society (International Society for the Understanding, Prevention, and treat
马斯协会(国际理解、预防和治疗协会)
  • 批准号:
    7914634
  • 财政年份:
    2010
  • 资助金额:
    $ 20万
  • 项目类别:
Identification and Therapy of Postpartum Depression
产后抑郁症的识别和治疗
  • 批准号:
    7483570
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Antimanic Use During Pregnancy
怀孕期间使用抗躁狂药
  • 批准号:
    7920852
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Identification and Therapy of Postpartum Depression
产后抑郁症的识别和治疗
  • 批准号:
    7902176
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Antimanic Use During Pregnancy
怀孕期间使用抗躁狂药
  • 批准号:
    7493577
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Identification and Therapy of Postpartum Depression
产后抑郁症的识别和治疗
  • 批准号:
    7035439
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Antimanic Use During Pregnancy
怀孕期间使用抗躁狂药
  • 批准号:
    7678965
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:
Identification and Therapy of Postpartum Depression
产后抑郁症的识别和治疗
  • 批准号:
    7282396
  • 财政年份:
    2006
  • 资助金额:
    $ 20万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 20万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 20万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了